MonoSol Rx, Strativa extend strategic relationship

WARREN, N.J. A subsidiary of a generic drug maker has entered into a new licensing and development agreement that grants the option to develop three new products for a drug delivery company.

Strativa has the option to license exclusive U.S. commercialization rights for the three additional oral soluble film products to be developed using MonoSol Rx's PharmFilm technology, the companies said in a joint statement.

The new option agreements are an extension of the strategic relationship between MonoSol Rx and Strativa, initiated in June 2008 when Strativa acquired exclusive U.S. commercialization rights to MonoSol Rx's ondansetron OSF, which will be marketed under the trade name Zuplenz. The new drug application for Zuplenz was accepted for review by the Food and Drug Administration in June 2009, and a response is expected in the first quarter 2010 as mandated by the Prescription Drug User Fee Act guidelines.